Niagen Bioscience has filed a prospectus to offer and sell common stock up to $50M. The filing, submitted to the SEC, outlines the company's plans to raise capital through the issuance of shares. This move is part of Niagen Bioscience's broader financial strategy to secure funding for future growth and operations.

Key Details of the Offering

The prospectus provides essential information about the proposed stock offering. Below is a summary of the key details:

Strategic Implications

By filing the prospectus, Niagen Bioscience aims to attract investors and raise capital. The funds generated from the stock offering will likely be used to support the company's operational and expansion initiatives. This filing reflects Niagen Bioscience's commitment to leveraging financial markets to achieve its business objectives.

Next Steps

The prospectus is now available for review by potential investors and regulatory bodies. Niagen Bioscience will proceed with the offering upon meeting all regulatory requirements and securing necessary approvals. The company's leadership is expected to provide further updates as the process advances.

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced the formal launch of the first drug candidate from its wholly owned subsidiary, NAD Pharmaceuticals Corp. The program targets accelerated aging and rare genetic diseases, with the initial indication being Ataxia Telangiectasia (A-T). The investigational product candidate, NB4168, is a patented therapeutic designed to have significantly increased bioavailability and a differentiated safety and pharmacokinetic profile compared to NRC. This launch marks the strategic expansion of Niagen Bioscience's NAD+ platform from cellular-health innovation into regulated drug development.

The program focuses on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function, and cellular stress responses, modulates in rare diseases where DNA misrepair and mitochondrial dysfunction are foundational causes. A-T is a rare genetic disease caused by mutations in the ATM gene, typically presenting in early childhood with progressive loss of motor coordination, impaired immune function, and a substantially elevated risk of cancer. There are currently no FDA-approved therapies for A-T, and treatment is largely limited to supportive care. The disease impacts roughly 1 in 40,000 people in the U.S. and 1 in 150,000 people in Europe.

NB4168 is a distinct, proprietary molecule designed for oral pharmaceutical development and is not commercially available as a supplement or approved drug. It is protected by Niagen Bioscience's patent portfolio, including a composition-of-matter patent. After oral administration, NB4168 is designed to safely deliver significantly increased doses of nicotinamide riboside (NR) to the bloodstream. NR enters cells directly where it is converted through the nicotinamide riboside kinase pathway into NAD+.

In nonclinical pharmacokinetic studies conducted to date, NB4168 has demonstrated substantially higher blood exposure to the active moiety compared with NR chloride. This supports its continued development as a more bioavailable pharmaceutical candidate. The program builds on published NR research in A-T, where two independent open-label clinical studies and several preclinical studies of NR chloride reported improvements in neurological measures and related biomarkers. While these studies were not conducted with NB4168 and were not registrational, they support the rationale for advancing NB4168 in rare pediatric diseases.

Strategic Development and De-risking

Rob Fried, Chief Executive Officer of Niagen Bioscience, stated that NB4168 represents the next step in translating the company's NAD+ leadership into pharmaceutical development. He noted that two independent, published clinical studies investigating the impact of NR on A-T have shown statistically significant results, alongside several non-clinical studies. Fried believes this body of work significantly de-risks the development pathway for NB4168, which was specifically developed for therapeutic applications.

Andrew Shao, Ph.D., Senior Vice President, Global Scientific & Regulatory Affairs, described the NB4168 program as focused and stage-gated. The strategy involves a proprietary molecule, a rare pediatric disease with high unmet need, a mechanistic link to NAD+ biology, and measurable pharmacokinetic and pharmacodynamic endpoints. The objective is to generate the pharmacological, toxicological, and eventually clinical evidence needed to determine whether NB4168 can provide meaningful benefit to patients.

Key Details of the NB4168 Program